Allergan loses Restasis patent protections in federal court decision
admin 16th October 2017 Uncategorised 0After stirring up a tribal licensing controversy, Allergan has run into a patent setback with big-selling eye medication Restasis. A federal judge invalidated exclusive protections for the drug—Allergan’s second biggest—boosting prospects for generic companies looking to challenge the branded drug’s blockbuster sales.
More: Allergan loses Restasis patent protections in federal court decision
Source: fierce